Healthcare Industry News: Solvay Pharmaceuticals
News Release - August 22, 2007
Dr. Garratt W. Ponder Named Vice President of Pharmaceutical Development for Atlanta-Based Tikvah Therapeutics, Inc.ATLANTA, Aug. 22, 2007 (Healthcare Sales & Marketing Network) -- Tikvah Therapeutics, Inc. has appointed Dr. Garratt W. Ponder Vice President of Pharmaceutical Development.
Dr. Ponder joins Tikvah Therapeutics with over twelve years of experience in analytical chemistry, process chemistry and pharmaceutical development at a variety of small, midsize, and large pharmaceutical companies. He was most recently Senior Director of Product Development at AtheroGenics, Inc. where he was responsible for Chemistry, Manufacturing and Control (CMC) activities for active pharmaceutical ingredient and drug product for in-licensing projects, including the compilation of CMC sections supporting regulatory filings in the U.S. and overseas. Dr. Ponder joined AtheroGenics in 2003 as Director of Product development. Prior to joining AtheroGenics, Dr. Ponder held positions of increasing responsibility at Endeavor Pharmaceuticals where he was responsible for all CMC activities from API through finished product, and at Solvay Pharmaceuticals, Inc. where he led CMC activities related to support of marketed products.
At Tikvah, Dr. Ponder will be responsible for all activities supporting production of developmental clinical supplies and, on approval, the manufacture of finished pharmaceutical products including supporting testing, release, and stability activities. As a member of the Senior Management Team and Corporate Officer, he will play a key role in helping to shape corporate strategy and assure tight integration and control of manufacturing and testing sites as well as internal laboratories to help us meet our business objectives.
``Garratt's extensive experience in chemistry, analytics, and dealing with challenging product-related production and testing issues along the entire spectrum of activities, spanning product development through commercial manufacture makes him ideal for this role,'' said Dr. Harold H. Shlevin, President and Chief Executive Officer of Tikvah Therapeutics, Inc. ``We are very delighted for someone of Garratt's caliber to join our management team and I am personally excited to have the opportunity to work with him again.''
Dr. Ponder earned his Ph.D. in Pharmaceutical Analysis at the University of Georgia, College of Pharmacy in 1995 and his B.S. in Chemistry in 1989. He is the author of numerous publications, presentations and on review panels of several peer-reviewed journals.
Bringing Hope to Life(sm)
Photo of Dr. Ponder is available upon request.
``Tikvah Therapeutics'', ``Bringing Hope to Life'', and the above logo design are trademarks of Tikvah Therapeutics, Inc., Atlanta, GA.
Source: Tikvah Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.